{"id":745563,"date":"2017-04-22T06:00:00","date_gmt":"2017-04-22T06:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-new-phase-2-data-on-investigational-triple-combination-therapy-mk-3682b-for-chronic-hepatitis-c\/"},"modified":"2025-11-07T01:26:34","modified_gmt":"2025-11-07T06:26:34","slug":"merck-announces-new-phase-2-data-on-investigational-triple-combination-therapy-mk-3682b-for-chronic-hepatitis-c","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-new-phase-2-data-on-investigational-triple-combination-therapy-mk-3682b-for-chronic-hepatitis-c\/","title":{"rendered":"Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C"},"content":{"rendered":"<p class=\"bwalignc\">       Findings Presented at The International Liver Congress\u2122 2017 Show        High Rates of Sustained Virologic Response (SVR12) in Genotype 1        Patients for Whom Direct-Acting Antiviral Therapy Had Previously Failed     <\/p>\n<p>\n      Merck (NYSE: MRK), known as MSD outside of the United States and Canada,<br \/>\n      today announced the first sustained virologic response<sup>1<\/sup> (SVR)<br \/>\n      results 12 weeks after completion of therapy (SVR12, considered<br \/>\n      virologic cure) from <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02613403&amp;esheet=51544888&amp;newsitemid=20170422005018&amp;lan=en-US&amp;anchor=C-SURGE&amp;index=1&amp;md5=5d5fdb29a9270766766d877f5c17c6bb\" rel=\"nofollow\"><br \/>\n<i>C-SURGE<\/i><br \/>\n<\/a>,<br \/>\n      an ongoing, open label Phase 2 clinical trial evaluating MK-3682B<br \/>\n      [uprifosbuvir (MK-3682)<sup>2<\/sup>\/grazoprevir<sup>3<\/sup>\/rusazvir<sup>4<\/sup>],<br \/>\n      the company\u2019s investigational triple-combination therapy in<br \/>\n      treatment-experienced patients with hepatitis C virus (HCV) genotype<br \/>\n      (GT) 1 infection for whom treatment with approved direct-acting<br \/>\n      antiviral regimens had failed. The study showed that 100 percent (43\/43)<br \/>\n      of patients who completed 16 weeks of treatment plus ribavirin (RBV)<br \/>\n      achieved SVR12 and 100 percent (49\/49) of patients who completed 24<br \/>\n      weeks of treatment achieved SVR12 (abstract PS-159). These results will<br \/>\n      be presented today at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Filc-congress.eu%2F&amp;esheet=51544888&amp;newsitemid=20170422005018&amp;lan=en-US&amp;anchor=The+International+Liver+Congress%E2%84%A2+2017&amp;index=2&amp;md5=d5aa947106f28ca46beed6aaa0241883\" rel=\"nofollow\">The<br \/>\n      International Liver Congress\u2122 2017<\/a>.\n    <\/p>\n<p>\n      \u201cDespite the significant progress made to address the worldwide epidemic<br \/>\n      of chronic hepatitis C infection, there remains a need for additional<br \/>\n      treatment options,\u201d said Dr. Heiner Wedemeyer, lead study investigator<br \/>\n      and research group leader in the department of gastroenterology,<br \/>\n      hepatology and endocrinology at Hannover Medical School, Germany.&nbsp;\u201cWe<br \/>\n      are encouraged by the high virologic cure rates in the<br \/>\n      difficult-to-treat patients observed in the <i>C-SURGE<\/i> study and<br \/>\n      look forward to further evaluation of this investigational<br \/>\n      triple-combination therapy.\u201d\n    <\/p>\n<p>\n      The Phase 2 <i>C-SURGE<\/i> study enrolled 94 patients who were<br \/>\n      randomized to receive a once-daily regimen of MK-3682B for either 16<br \/>\n      weeks with RBV (n=45) or 24 weeks without RBV (n=49); one patient in the<br \/>\n      16-week arm withdrew prior to starting treatment. Of the 93 patients who<br \/>\n      received treatment (full analysis set), 57 had previously received a<br \/>\n      regimen of ledipasvir\/sofosbuvir (LDV\/SOF) for 12 to 24 weeks, 14 had<br \/>\n      previously received LDV\/SOF for 8 weeks and 22 had previously received<br \/>\n      ZEPATIER<sup>\u00ae<\/sup> (elbasvir and grazoprevir) for 12 weeks.<br \/>\n      Seventy-eight patients who received treatment had at least one baseline<br \/>\n      NS5A resistance-associated substitution (RAS) at positions 28, 30, 31 or<br \/>\n      93. Eighty patients who received treatment in <i>C-SURGE<\/i> had GT1a<br \/>\n      infection, and 40 patients had compensated cirrhosis. In the full<br \/>\n      analysis set, 98 percent of patients who received MK-3682B for 16 weeks<br \/>\n      with RBV (43\/44) and 100 percent of patients who received MK-3682B for<br \/>\n      24 weeks without RBV (49\/49) achieved SVR12.\n    <\/p>\n<p>\n      Results from the modified full analysis set, which excludes one patient<br \/>\n      in the 16-week arm who withdrew after three doses of treatment, show<br \/>\n      that 100 percent of patients receiving treatment with MK-3682B for 16<br \/>\n      weeks with RBV (43\/43) and 100 percent of patients receiving treatment<br \/>\n      with MK-3682B for 24 weeks without RBV (49\/49) achieved SVR12.\n    <\/p>\n<p>\n      Across the combined treatment arms, the most common adverse events (AEs)<br \/>\n      reported in the full analysis set were fatigue (35%), headache (13%),<br \/>\n      diarrhea (9%), rash (9%) and pruritus (5%). There were no drug-related<br \/>\n      serious AEs, and no patients discontinued treatment due to a<br \/>\n      drug-related AE.\n    <\/p>\n<p>\n      SVR8 <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mrknewsroom.com%2Fnews-release%2Fhepatitis-c-newsroom%2Fmerck-announces-findings-investigational-triple-combination-chroni&amp;esheet=51544888&amp;newsitemid=20170422005018&amp;lan=en-US&amp;anchor=results&amp;index=3&amp;md5=ebadb1cc7802f7f48337e7ae3d588301\" rel=\"nofollow\">results<\/a><br \/>\n      from the <i>C-SURGE<\/i> study were previously presented at The Liver<br \/>\n      Meeting<sup>\u00ae<\/sup> 2016.\n    <\/p>\n<p>\n      <b>About MK-3682B<\/b>\n    <\/p>\n<p>\n      MK-3682B is Merck\u2019s investigational triple-combination therapy in Phase<br \/>\n      2 development for the treatment of chronic HCV infection. MK-3682B<br \/>\n      combines an HCV nucleotide analogue NS5B polymerase inhibitor (MK-3682),<br \/>\n      an HCV NS3\/4A protease inhibitor (grazoprevir, MK-5172) and an HCV NS5A<br \/>\n      inhibitor (ruzasvir, MK-8408).\n    <\/p>\n<p>\n      <b>About ZEPATIER<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (elbasvir and grazoprevir)<br \/>\n      50mg\/100mg Tablets<\/b>\n    <\/p>\n<p>\n      ZEPATIER is a fixed-dose combination product containing elbasvir, a HCV<br \/>\n      NS5A inhibitor, and grazoprevir, an HCV NS3\/4A protease inhibitor. In<br \/>\n      the United States, ZEPATIER is indicated for the treatment of chronic<br \/>\n      HCV GT1 or 4 infection in adults. ZEPATIER is indicated for use with<br \/>\n      ribavirin (RBV) in certain patient populations.\n    <\/p>\n<p>\n      <b>Selected Safety Information about ZEPATIER (elbasvir and grazoprevir)<\/b>\n    <\/p>\n<p>\n      The US Prescribing Information for ZEPATIER contains a Boxed Warning<br \/>\n      about the risk of hepatitis B virus (HBV) reactivation in patients<br \/>\n      coinfected with HCV and HBV. Healthcare professionals should test all<br \/>\n      patients for evidence of current or prior HBV infection by measuring<br \/>\n      hepatitis B surface antigen (HBsAg) and hepatitis B core antibody<br \/>\n      (anti-HBc) before initiating treatment with ZEPATIER. HBV reactivation<br \/>\n      has been reported in HCV\/HBV coinfected patients who were undergoing or<br \/>\n      had completed treatment with HCV direct-acting antivirals and were not<br \/>\n      receiving HBV antiviral therapy. Some cases have resulted in fulminant<br \/>\n      hepatitis, hepatic failure, and death. Healthcare professionals should<br \/>\n      monitor HCV\/HBV coinfected patients for clinical and laboratory signs of<br \/>\n      hepatitis flare or HBV reactivation during HCV treatment and<br \/>\n      post-treatment follow-up. Healthcare professionals should initiate<br \/>\n      appropriate patient management for HBV infection as clinically indicated.\n    <\/p>\n<p>\n      HBV reactivation has been reported in HBsAg positive patients and also<br \/>\n      in patients with serologic evidence of resolved HBV infection (ie, HBsAg<br \/>\n      negative and anti-HBc positive). The risk of HBV reactivation may be<br \/>\n      increased in patients receiving some immunosuppressant or<br \/>\n      chemotherapeutic agents. HBV reactivation is characterized as an abrupt<br \/>\n      increase in HBV replication manifesting as a rapid increase in serum HBV<br \/>\n      DNA level. In patients with resolved HBV infection, reappearance of<br \/>\n      HBsAg can occur. Reactivation of HBV replication may be accompanied by<br \/>\n      hepatitis, ie, increases in aminotransferase levels and, in severe<br \/>\n      cases, increases in bilirubin levels, liver failure, and death can occur.\n    <\/p>\n<p>\n      ZEPATIER is not for use in patients with moderate or severe hepatic<br \/>\n      impairment (Child Pugh B or C). ZEPATIER is also not for use with<br \/>\n      inhibitors of organic anion transporting polypeptides 1B1\/3 (OATP1B1\/3)<br \/>\n      that are known or expected to significantly increase grazoprevir plasma<br \/>\n      concentrations (e.g., atazanavir, darunavir, lopinavir, saquinavir,<br \/>\n      tipranavir, cyclosporine), strong cytochrome P450 3A (CYP3A) inducers<br \/>\n      (e.g., carbamazepine, phenytoin, rifampin, St. John\u2019s Wort), and<br \/>\n      efavirenz. If ZEPATIER is administered with RBV, healthcare<br \/>\n      professionals should refer to the prescribing information for RBV as the<br \/>\n      contraindications, warnings and precautions, adverse reactions and<br \/>\n      dosing for RBV also apply to this combination regimen.\n    <\/p>\n<p>\n      Elevations of alanine transaminase (ALT) to greater than 5 times the<br \/>\n      upper limit of normal (ULN) occurred in 1% of subjects, generally at or<br \/>\n      after treatment week 8. These late ALT elevations were typically<br \/>\n      asymptomatic and most resolved with ongoing or completion of therapy.<br \/>\n      Healthcare professionals should perform hepatic lab testing on patients<br \/>\n      prior to therapy, at treatment week 8, and as clinically indicated. For<br \/>\n      patients receiving 16 weeks of therapy, additional hepatic lab testing<br \/>\n      should be performed at treatment week 12.\n    <\/p>\n<p>\n      Patients should be instructed to consult their healthcare professional<br \/>\n      without delay if they have onset of fatigue, weakness, lack of appetite,<br \/>\n      nausea and vomiting, jaundice or discolored feces. Healthcare providers<br \/>\n      should consider discontinuing ZEPATIER<sup>\u00ae<\/sup> (elbasvir and<br \/>\n      grazoprevir) if ALT levels remain persistently greater than 10 times<br \/>\n      ULN. ZEPATIER should be discontinued if ALT elevation is accompanied by<br \/>\n      signs or symptoms of liver inflammation or increasing conjugated<br \/>\n      bilirubin, alkaline phosphatase, or international normalized ratio.\n    <\/p>\n<p>\n      The concomitant use of ZEPATIER with certain drugs may lead to adverse<br \/>\n      reactions or reduced therapeutic effect due to drug interactions.<br \/>\n      Certain strong CYP3A inhibitors may increase the plasma concentration of<br \/>\n      ZEPATIER, leading to possibly clinically significant adverse reactions.<br \/>\n      Moderate CYP3A inducers may decrease the plasma concentration of<br \/>\n      ZEPATIER, leading to reduced therapeutic effect and possible development<br \/>\n      of resistance. Coadministration of ZEPATIER with these drugs is not<br \/>\n      recommended. Physicians should consult the Prescribing Information for<br \/>\n      potential drug interactions.\n    <\/p>\n<p>\n      In subjects receiving ZEPATIER for 12 weeks, the most commonly reported<br \/>\n      adverse reactions of all intensity (greater than or equal to 5% in<br \/>\n      placebo-controlled trials) were fatigue, headache and nausea. In<br \/>\n      subjects receiving ZEPATIER with RBV for 16 weeks, the most commonly<br \/>\n      reported adverse reactions of moderate or severe intensity (greater than<br \/>\n      or equal to 5%) were anemia and headache.\n    <\/p>\n<p>\n      <b>Selected Dosage and Administration Information for ZEPATIER<\/b>\n    <\/p>\n<p>\n      ZEPATIER is a single tablet taken once daily. The recommended dosing is<br \/>\n      12 or 16 weeks with or without RBV, depending on HCV genotype, prior<br \/>\n      treatment history and, for patients with genotype 1a infection, presence<br \/>\n      of certain baseline NS5A resistance-associated polymorphisms. See<br \/>\n      Prescribing Information for ZEPATIER for specific dosage regimens and<br \/>\n      durations. Refer to RBV prescribing information for RBV dosing and<br \/>\n      dosage modifications when ZEPATIER is given with RBV. To determine<br \/>\n      dosage regimen and duration of ZEPATIER for genotype 1a patients,<br \/>\n      testing for the presence of virus with one or more baseline NS5A<br \/>\n      resistance-associated polymorphisms at positions 28, 30, 31, or 93 is<br \/>\n      recommended prior to initiating treatment.\n    <\/p>\n<p>\n      <b>Merck\u2019s Commitment to HCV<\/b>\n    <\/p>\n<p>\n      For more than 30 years, Merck has been at the forefront of the response<br \/>\n      to the HCV epidemic. Merck\u2019s chronic HCV clinical development programs<br \/>\n      have included more than 135 clinical trials in approximately 40<br \/>\n      countries and have enrolled nearly 10,000 participants. As part of our<br \/>\n      longstanding leadership in infectious diseases, Merck collaborates with<br \/>\n      the scientific and patient communities to develop and deliver innovative<br \/>\n      solutions to support people living with chronic HCV worldwide.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      bringing forward medicines and vaccines for many of the world&#8217;s most<br \/>\n      challenging diseases. Through our prescription medicines, vaccines,<br \/>\n      biologic therapies and animal health products, we work with customers<br \/>\n      and operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      Today, Merck continues to be at the forefront of research to advance the<br \/>\n      prevention and treatment of diseases that threaten people and<br \/>\n      communities around the world &#8211; including cancer, cardio-metabolic<br \/>\n      diseases, emerging animal diseases, Alzheimer&#8217;s disease and infectious<br \/>\n      diseases including HIV and Ebola. For more information, visit&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Findex.html&amp;esheet=51544888&amp;newsitemid=20170422005018&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=4&amp;md5=39a5fae266eb3686f41a2a930cec8f97\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and&nbsp;connect with us on&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51544888&amp;newsitemid=20170422005018&amp;lan=en-US&amp;anchor=Twitter&amp;index=5&amp;md5=7643dd96574edb5edf5e7ec82efa0aec\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51544888&amp;newsitemid=20170422005018&amp;lan=en-US&amp;anchor=Facebook&amp;index=6&amp;md5=ab3a3080731e1e4615cdb87a6f60c6f8\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51544888&amp;newsitemid=20170422005018&amp;lan=en-US&amp;anchor=Instagram&amp;index=7&amp;md5=35a773d58a789692ae164a8aff5499af\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51544888&amp;newsitemid=20170422005018&amp;lan=en-US&amp;anchor=YouTube&amp;index=8&amp;md5=981727db2be4a120f8d36d298ee82b3c\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51544888&amp;newsitemid=20170422005018&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=9&amp;md5=25e79e596897fb6c9747c41a7da3c053\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2016 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51544888&amp;newsitemid=20170422005018&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=10&amp;md5=cb9887ca50922d7324232528d4c79462\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for ZEPATIER (elbasvir and<br \/>\n      grazoprevir) at <\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzepatier%2Fzepatier_pi.pdf&amp;esheet=51544888&amp;newsitemid=20170422005018&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzepatier%2Fzepatier_pi.pdf&amp;index=11&amp;md5=bd07fe8f41acd7b9c7dc9074553275c0\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/z\/zepatier\/zepatier_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b><br \/>\n      and the Patient Information for ZEPATIER at <\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzepatier%2Fzepatier_ppi.pdf&amp;esheet=51544888&amp;newsitemid=20170422005018&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fz%2Fzepatier%2Fzepatier_ppi.pdf&amp;index=12&amp;md5=1419698776e3bad49767d674fc908148\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/z\/zepatier\/zepatier_ppi.pdf<\/b><br \/>\n<\/a>\n    <\/p>\n<p>\n      ______________________<br \/>\n<sup>1<\/sup> Measured as HCV RNA less than<br \/>\n      15 IU\/mL.<br \/>\n<sup>2<\/sup> MK-3682 is an HCV nucleotide analogue NS5B<br \/>\n      polymerase inhibitor.<br \/>\n<sup>3<\/sup> Grazoprevir is an HCV NS3\/4A<br \/>\n      protease inhibitor (100mg).<br \/>\n<sup>4<\/sup> Rusazvir (MK-8408) is an<br \/>\n      HCV NS5A inhibitor.\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20170422005018r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Doris Li, 908-740-1903<br \/>Michael Close,        267-305-1211<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>Amy        Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Findings Presented at The International Liver Congress\u2122 2017 Show High Rates of Sustained Virologic Response (SVR12) in Genotype 1 Patients for Whom Direct-Acting Antiviral Therapy Had Previously Failed Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first sustained virologic response1 (SVR) results 12 weeks after completion of therapy (SVR12, considered virologic cure) from C-SURGE , an ongoing, open label Phase 2 clinical trial evaluating MK-3682B [uprifosbuvir (MK-3682)2\/grazoprevir3\/rusazvir4], the company\u2019s investigational triple-combination therapy in treatment-experienced patients with hepatitis C virus (HCV) genotype (GT) 1 infection for whom treatment with approved direct-acting antiviral regimens had failed. The study showed that 100 percent (43\/43) of patients who completed 16 weeks of treatment plus ribavirin (RBV) achieved SVR12 and 100 percent (49\/49) of patients who completed 24 weeks of treatment achieved SVR12 (abstract<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-745563","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-new-phase-2-data-on-investigational-triple-combination-therapy-mk-3682b-for-chronic-hepatitis-c\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Findings Presented at The International Liver Congress\u2122 2017 Show High Rates of Sustained Virologic Response (SVR12) in Genotype 1 Patients for Whom Direct-Acting Antiviral Therapy Had Previously Failed Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first sustained virologic response1 (SVR) results 12 weeks after completion of therapy (SVR12, considered virologic cure) from C-SURGE , an ongoing, open label Phase 2 clinical trial evaluating MK-3682B [uprifosbuvir (MK-3682)2\/grazoprevir3\/rusazvir4], the company\u2019s investigational triple-combination therapy in treatment-experienced patients with hepatitis C virus (HCV) genotype (GT) 1 infection for whom treatment with approved direct-acting antiviral regimens had failed. The study showed that 100 percent (43\/43) of patients who completed 16 weeks of treatment plus ribavirin (RBV) achieved SVR12 and 100 percent (49\/49) of patients who completed 24 weeks of treatment achieved SVR12 (abstract\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-new-phase-2-data-on-investigational-triple-combination-therapy-mk-3682b-for-chronic-hepatitis-c\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-new-phase-2-data-on-investigational-triple-combination-therapy-mk-3682b-for-chronic-hepatitis-c\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-new-phase-2-data-on-investigational-triple-combination-therapy-mk-3682b-for-chronic-hepatitis-c\\\/\",\"name\":\"Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-04-22T06:00:00+00:00\",\"dateModified\":\"2025-11-07T06:26:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-new-phase-2-data-on-investigational-triple-combination-therapy-mk-3682b-for-chronic-hepatitis-c\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-new-phase-2-data-on-investigational-triple-combination-therapy-mk-3682b-for-chronic-hepatitis-c\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-new-phase-2-data-on-investigational-triple-combination-therapy-mk-3682b-for-chronic-hepatitis-c\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-new-phase-2-data-on-investigational-triple-combination-therapy-mk-3682b-for-chronic-hepatitis-c\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C - Merck.com","og_description":"Findings Presented at The International Liver Congress\u2122 2017 Show High Rates of Sustained Virologic Response (SVR12) in Genotype 1 Patients for Whom Direct-Acting Antiviral Therapy Had Previously Failed Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first sustained virologic response1 (SVR) results 12 weeks after completion of therapy (SVR12, considered virologic cure) from C-SURGE , an ongoing, open label Phase 2 clinical trial evaluating MK-3682B [uprifosbuvir (MK-3682)2\/grazoprevir3\/rusazvir4], the company\u2019s investigational triple-combination therapy in treatment-experienced patients with hepatitis C virus (HCV) genotype (GT) 1 infection for whom treatment with approved direct-acting antiviral regimens had failed. The study showed that 100 percent (43\/43) of patients who completed 16 weeks of treatment plus ribavirin (RBV) achieved SVR12 and 100 percent (49\/49) of patients who completed 24 weeks of treatment achieved SVR12 (abstract","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-new-phase-2-data-on-investigational-triple-combination-therapy-mk-3682b-for-chronic-hepatitis-c\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:34+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-new-phase-2-data-on-investigational-triple-combination-therapy-mk-3682b-for-chronic-hepatitis-c\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-new-phase-2-data-on-investigational-triple-combination-therapy-mk-3682b-for-chronic-hepatitis-c\/","name":"Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-04-22T06:00:00+00:00","dateModified":"2025-11-07T06:26:34+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-new-phase-2-data-on-investigational-triple-combination-therapy-mk-3682b-for-chronic-hepatitis-c\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-new-phase-2-data-on-investigational-triple-combination-therapy-mk-3682b-for-chronic-hepatitis-c\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-new-phase-2-data-on-investigational-triple-combination-therapy-mk-3682b-for-chronic-hepatitis-c\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"834a7cd4-8742-437a-aba5-2d6ad2fb8306","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Announces-New-Phase-2-Data-on-Investigational-Triple-Combination-Therapy-MK-3682B-for-Chronic-Hepatitis-C-2017.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745563","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745563\/revisions"}],"predecessor-version":[{"id":3674928,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745563\/revisions\/3674928"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745563"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745563"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}